Pain

Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of theAmerican Society of Clinical Oncology has published the earlyresults of a clinical study conducted by Dr. Siu-Fun Wong, and hercolleagues, which concluded that the topical gel, Regenecare(R),caused a statistically significant reduction in the pain anditching of a rash that results from the use of anti-cancer drugsknown as EGFR...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality ofCompany's Once-Daily Tramadol to be Published in BiopharmaceuticsJournal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc.today announced that it will present a poster discussing the dosetitration of its once-daily formulation of tramadol at the 3rdInternational Forum on Pain Medicine to be held June 28 to J...

CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) today announced preliminary results ofits randomized, blinded, placebo-controlled clinical trial ofCRx-150 in patients with rheumatoid arthritis (RA). The trialcompared CRx-150 plus a disease-modifying anti-rheumatic drug(DMARD) to placebo plus DMARD (control) in subjects with active RA.In the prelimin...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...

Gabapentin Shown Effective for Fibromyalgia Pain

BETHESDA, Md., June 11, 2007--New research supported by theNational Institutes of Healths National Institute of Arthritis andMusculoskeletal and Skin Diseases (NIAMS) shows that theanticonvulsant medication , which is used for certaintypes of seizures, can be an effective treatment for the pain andother symptoms associ...

Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer

<p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphenate: none">BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spraycould stop thousands of patients with cancer from sufferingunnecessary pain; it was reported today1 at the 10th Congress ofthe European Association for Palliative Care, Budapest, 7–9June. The study investigated whether this first in class novelformulation c...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced the presentation ofPhase III data, including efficacy, safety and improvements inpatient-centered outcomes in patients with diabetic peripheralneuropathic (DPN) pain treated with the investigational drugZenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptorantagonist and sigma-1...

NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)

SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ --NeurogesX, Inc. announced today the presentation of clinical datafrom a positive Phase 3 trial in postherpetic neuralgia (PHN).Misha-Miroslav Backonja, M.D., Professor of Neurology at Universityof Wisconsin in Madison and lead academic investigator in theNeurogesX trial, plans to present the results of the study in aJune 8 poster...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from aPhase II study presented for the first time at the AmericanHeadache Society (AHS) annual meeting showed that MK-0974, aninvestigational oral calcitonin gene-related peptide (CGRP)receptor antagonist, significantly improved migraine pain relieftwo hours after dosing compared to placebo, and the relief wassustained through 24 hour...

Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study

Patients Using ROX-888 Required Significantly Less Morphine AfterMajor Abdominal Surgery Company On Track To File NDA In 2008 MENLO PARK, CA (June 6, 2007) – ROXROPHARMA Inc. said today that ROX-888, its novel intranasalanalgesic, rapidly and effectively eased pain and was welltolerated by patients who had undergone major abdominal surgery ina Phase 3 clinical study....

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - JavelinPharmaceuticals, Inc. (AMEX: JAV), a leading developer of novelproducts for pain control, today announced that its Phase 2multi-dose study of Rylomine was published in Pain Medicine, theofficial journal of The American Academy of Pain Medicine. Thearticle, entitled, "Analgesic Efficacy and Safety ofMorphine-Chitosan Nasal Solution in P...

In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression

SAN DIEGO, California, 23 May 2007 - The antidepressant duloxetinehydrochloride was equally effective in reducing painful symptoms indepressed patients who did not respond, or responded onlypartially, to treatment with a selective serotonin reuptakeinhibitor (SSRI), regardless of whether those patients wereswitched from an SSRI abruptly or gradually. This newdata was presented t...

CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB)announced today that Dr. Yin Chen, Chief Scientific Officer willpresent an update on preclinical animal data for DNA vaccines madeusing the Company's proprietary synDNA(TM) technology at the 2007DNA Vaccines conference to be held in Malaga, Spain between May 23and May 25. Dr. Chen comments, "We have successfully conducted t...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced Phase III data on theefficacy, safety and improvements in patient-centered outcomes inpatients with diabetic peripheral neuropathic (DPN) pain treatedwith the investigational drug Zenvia(TM) (dextromethorphan /quinidine) will be presented in two scientific posters at theSecond Internation...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation announced today that it will present new data forEpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th AnnualScientific Meeting of the American Pain Society in Washington D.C.EpiCept NP-1 is a patented topical cream formulation of twoFDA-approved drugs,...

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced top-line results from its randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) in opioid naivepatients with post-operative pain following orthopedic surgery.AeroLEF(TM) met the pr...

Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain

New Analysis Examines Impact of Pain on Sleep Interference INDIANAPOLIS, May 03, 2007 /PRNewswire-FirstCall/ -- Data from apooled analysis of three studies suggest that in patients with paincaused by diabetic nerve damage, or diabetic peripheral neuropathy,who are treated with Cymbalta (duloxetine HCl), improvements inboth average daily pain and night pain severity were associatedwith les...

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patientstreated with Pfizer's Lyrica reduced their pain by 50 percent ormore compared with placebo, according to study results presentedtoday at the American Academy of Neurology annual meeting.Clinically, this outcome would equate to a patient with severe painreporting a reduction to mild to moderate pain. Fibromyalgia is one of t...

Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon,Inc. Phase 3 clinical trial presented today at the 59th AnnualMeeting of the American Academy of Neurology in Boston highlightsdata demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II]is beneficial for the treatment of breakthrough pain in patientswith...

Labtec’s Next Generation Pain Patch Successful in Clinical Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld,Germany), a specialty pharmaceutics company announces positiveresults from a multiple dose clinical study for their proprietarySufentanil transdermal patch. “Today, we are pleased to announce the successfulcompletion of the second clinical trial for our SufentanilTDS®. Our goal for this program was to complete th...

Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced positive top-lineresults from the company's Phase III clinical trial evaluating theinvestigational drug Zenvia(TM) (dextromethorphanhydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonist andsigma-1 agonist, in diabetic neuropathic pain. The primary endpoint of the trial was based...

Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial

Iontophoretic Drug Delivery System, dermal patch and a directcurrent power source with lidocaine and epinephrine (IDDS) SEATTLE, March 20, 2007 /PRNewswire/ -- Dharma Therapeutics,Inc., ("Dharma") Seattle, WA, a transdermal drug delivery companyand wholly owned subsidiary of Transcutaneous Technologies, Inc.("TTI"), Tokyo, Japan announced that its active transdermaldelivery te...

In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression

MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, ata once-daily dose of 60 mg, significantly reduced non-specific painand emotional symptoms associated with depression in a new,eight-week, placebo-controlled study of 327 adult patients with atleast moderate pain and major depression. The results werepresented today at the 15th European Congress of Psychiatry (AEP)in Madrid,...

New Phase IV Clinical Study Indicates LidoSite Provides Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings(Nevada), Inc. (OTCBB: VYHN), today announced results from a newphase IV "Open Label" clinical study demonstrating that LidoSite,the first FDA approved active patch for dermal analgesia, providedbetter pain relief to more than 73 percent of patients receivinginjections of hyaluronic acid during treatment for osteoarthritisthan...

GenoMed Prevents Sickle Cell Pain for Over a Year

ST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC PinkSheets:GMED), the Next Generation Disease Management company whosebusiness is public health(TM), announced today publication of acase report of a sickle cell patient whose pain has disappeared forover a year thanks to GenoMed's treatment. The patient is a middle-aged African American woman who foryears required multiple pain pill...